Jean Mosser
Overview
Explore the profile of Jean Mosser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obacz J, Archambeau J, Lafont E, Nivet M, Martin S, Aubry M, et al.
Neuro Oncol
. 2023 Dec;
26(5):858-871.
PMID: 38153426
Background: Intrinsic or environmental stresses trigger the accumulation of improperly folded proteins in the endoplasmic reticulum (ER), leading to ER stress. To cope with this, cells have evolved an adaptive...
2.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2023 Mar;
9(8):692.
PMID: 36997420
No abstract available.
3.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, et al.
EMBO Mol Med
. 2023 Feb;
15(2):e16731.
PMID: 36752056
No abstract available.
4.
Bikfalvi A, Alves da Costa C, Avril T, Barnier J, Bauchet L, Brisson L, et al.
Trends Cancer
. 2022 Nov;
9(1):9-27.
PMID: 36400694
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has been recognized as an...
5.
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
Li B, Wang J, Liu F, Li R, Hu W, Etcheverry A, et al.
J Oncol
. 2022 Jun;
2022:6345160.
PMID: 35712126
Objective: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods: Non-G-CIMP GBM datasets...
6.
Roux B, Picou F, Debeissat C, Koubi M, Gallay N, Hirsch P, et al.
Cancer Gene Ther
. 2022 Feb;
29(8-9):1263-1275.
PMID: 35194200
DNA methylation, a major biological process regulating the transcription, contributes to the pathophysiology of hematologic malignancies, and hypomethylating agents are commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid...
7.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, et al.
EMBO Mol Med
. 2022 Jan;
14(2):e15622.
PMID: 35014200
No abstract available.
8.
Yin A, Shang Z, Etcheverry A, He Y, Aubry M, Lu N, et al.
Oncoimmunology
. 2021 Apr;
10(1):1902071.
PMID: 33854822
The clinical and molecular implications of DNA methylation alterations remain unclear among the majority of glioblastomas (GBMs) without glioma-CpGs island methylator phenotype (G-CIMP); integrative multi-level molecular profiling may provide useful...
9.
Lachat C, Bruyere D, Etcheverry A, Aubry M, Mosser J, Warda W, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33291363
The role of Epigenetics in Epithelial Mesenchymal Transition (EMT) has recently emerged. Two epigenetic enzymes with paradoxical roles have previously been associated to EMT, EZH2 (Enhancer of Zeste 2 Polycomb...
10.
Le Reste P, Pineau R, Voutetakis K, Samal J, Jegou G, Lhomond S, et al.
Cancer Lett
. 2020 Sep;
494:73-83.
PMID: 32882336
Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for success in...